Call for proposals
Innovative Medicines Initiative (IMI): “IMI Joint Undertaking 2 Call 12”
- H2020-JTI-IMI2-2017-12-TWO-STAGE.
Objective and description
A
new call for proposals has been published under the Innovative
Medicines Initiative (IMI): “IMI Joint Undertaking 2 Call 12” -
H2020-JTI-IMI2-2017-12-TWO-STAGE.
The Innovative Medicines Initiative (IMI) is
a jointly funded partnership between the European Union, represented by
the European Commission, and the European Federation of Pharmaceutical
Industries and Associations (EFPIA).
The IMI 2 Joint Undertaking (IMI2 JU) aims to
support research related to the future of medicine should in areas
where societal, public health and biomedical industry competitiveness
goals are aligned and require the pooling of resources and greater
collaboration between the public and private sectors, with the
involvement of small and mediumsized enterprises (SMEs). The areas
should be of public health interest, as identified by the World Health
Organisation (WHO) report on priority medicines for Europe and the
World.
The call for proposals refers to the following topics:
1. IMI2-2017-12-01:
Development and validation of technology enabled, quantitative and
sensitive measures of functional decline in people with early stage
Alzheimer’s Disease (RADAR-AD):
The
main goal of the action to be created from this topic is to develop a
digital platform to measure a valid and meaningful combination of
smartphone, wearable and/or home sensor based parameters that can detect
subtle functional deficits in early Alzheimer’s patients (mild AD, MCI
or earlier), in the context of AD progression.
2. IMI2-2017-12-02: FAIRification of IMI and EFPIA data
The
project will focus on IMI projects that have data that is
scientifically valuable and amenable to being made FAIR. It is expected
that the databases of more than 20 IMI projects will be made FAIR in
this project. All IMI projects will be assessed for the presence of data
that requires FAIRification, though it should be noted that IMI2
projects are already required to manage their data according to similar
protocols.
3. IMI2-2017-12-03: Development of sensitive and validated clinical endpoints in primary Sjögren’s Syndrome (pSS)
The
overarching objective of this proposal is to develop sensitive and
validated clinical endpoints for use in future clinical trials of pSS.
The goal is to identify and eventually propose a single composite
endpoint that could provide evidence of disease-modifying and
symptomatic efficacy. The major scope of this effort will be the
identification, development and validation of pSS-related outcome
measures including clinical, PRO, laboratory, bio-behavioural activity
and imaging parameters
4. IMI2-2017-12-04: European Health Data Network (EHDN)
The
EHDN project is a critical enabling component of the IMI BD4BO
programme and is responsible for supporting the research aspects of the
other BD4BO projects in delivering the vision of large scale medical
outcomes research. Therefore, the EHDN should focus on being an enabling
project with the aim of developing a data network to allow other
researchers to ‘find’ and safely ‘reuse’ data.
5. IMI2-2017-12-05: Analysing the infectious disease burden and the use of vaccines to improve healthy years in aging populations
The
scope of the project is to obtain a clear picture on the infectious
disease burden in an aging population (50 years + group), quantify the
problem such as number and type of hospitalisations and medical visits
when the 50 years + group is exposed to the health care system,
understand this evolution over the coming years, obtain a better insight
in the immune response in the age-group of 65 years +, develop
cost-benefit predictions based on an extended vaccination programme,
better control the burden in that age-group through simulations with
advanced disease models, and finally, develop strategies to educate all
stakeholders working with the elderly.
6. IMI2-2017-12-06:
Discovery and characterisation of blood-brain barrier (BBB) targets and
transport mechanisms for brain delivery of therapeutics to treat
neurodegenerative & metabolic diseases
The
overall aim of the proposed research topic is to further the
understanding of the BBB in health and disease states towards the
development of innovative brain delivery systems, especially for
biopharmaceuticals
(e.g., peptides, antibodies, etc.) and the identification of novel
disease drug targets (Alzheimer’s Disease, PD, etc.)
7. IMI2-2017-12-07: European Screening Centre: unique library for attractive biology (ESCulab)
The
aim of this project is to combine the large high-quality compound
libraries held by the pharmaceutical industry with the innovative
targets held by academic organisations in a public-private partnership
to create an ideal platform to transform biological discoveries into
medicines. The project is intended to lower the hurdles for academic
groups and SMEs to translate early innovative biology into chemical
series that have the potential to be optimised into drug candidates.
Eligible applicants
Only the following participants shall be eligible for funding from the Innovative Medicines Initiative 2 Joint Undertaking:
1. legal entities established in a Member State or an associated country, or created under Union law and which fall within one of the following categories:
· micro,
small and medium-sized enterprises and other companies with an annual
turnover of EUR 500 million or less, the latter not being affiliated
entities of companies with an annual turnover of more than 500 million;
the definition of ‘affiliated entities’ within the meaning of Article
2(1)(2) of Regulation (EU) No 1290/2013 shall apply mutatis mutandis;
· secondary and higher education establishments;
· non-profit
organisations, including those carrying out research or technological
development as one of their main objectives or those that are patient
organisations.
2. the Joint Research Centre
3. international European interest organisations
Part
C of the General Annexes to the Horizon 2020 – Work Programme 2016 –
2017 apply mutatis mutandis for the actions covered by this Call for
proposals. Since the aforementioned calls refer to Research and Innovation actions eligible are consortia of at least three legal entities.
Each of the three must be established in a different EU Member State or
Horizon 2020 associated country. All three legal entities must be
independent of each other.
Budget and duration
The total indicative budget for “Innovative Medicines Initiative Call 12” - H2020-JTI-IMI2-2017-12-TWO-STAGE is EUR 62 362 000 from EFPIA companies and IMI2 JU Associated Partners and EUR 64 077 000 from IMI2 JU.
The budget for each topic is distributed as follows:
1. IMI2-2017-12-01:
Development and validation of technology enabled, quantitative and
sensitive measures of functional decline in people with early stage
Alzheimer’s Disease (RADAR-AD):
The indicative in-kind contribution is EUR 3 555 000.
This contribution comprises an indicative EFPIA in-kind contribution of
EUR 2 830 000 and an indicative IMI2 Associated Partners in-kind
contribution of EUR 725 000.
Due
to the global nature of the participating industry partners it is
anticipated that some elements of the contributions will be non-EU
in-kind contribution.
The financial contribution from IMI2 is a maximum of EUR 5 000 000.
The indicative duration of the action is 36 months.
2. IMI2-2017-12-02: FAIRification of IMI and EFPIA data
The indicative EFPIA in-kind contribution is EUR 3 730 000.
The financial contribution from IMI2 is a maximum of EUR 4 000 000.
The indicative duration of the action is 36 months.
3. IMI2-2017-12-03: Development of sensitive and validated clinical endpoints in primary Sjögren’s Syndrome (pSS)
The indicative EFPIA in-kind contribution is EUR 8 200 000.
Due
to the global nature of the participating industry partners it is
anticipated that some elements of the contributions will be non-EU/H2020
Associated Countries in-kind contributions.
The financial contribution from IMI2 is a maximum of EUR 8 200 000.
The indicative duration of the action is 72 months.
4. IMI2-2017-12-04: European Health Data Network (EHDN)
The indicative EFPIA contribution is EUR 14 127 000.
The financial contribution from IMI2 JU is a maximum of EUR 14 127 000.
The indicative duration of the action is 60 months.
5. IMI2-2017-12-05: Analysing the infectious disease burden and the use of vaccines to improve healthy years in aging populations
The indicative EFPIA in-kind contribution is EUR 5 500 000.
The financial contribution from IMI2 is a maximum of EUR 5 500 000.
The indicative duration of the action is 60 months.
6. IMI2-2017-12-06:
Discovery and characterisation of blood-brain barrier (BBB) targets and
transport mechanisms for brain delivery of therapeutics to treat
neurodegenerative & metabolic diseases
The indicative EFPIA in-kind contribution is EUR 9 000 000.
Due
to the global nature of the participating industry partners, it is
anticipated that some elements of the contributions will be non-EU/H2020
Associated Countries in-kind contributions.
The financial contribution from IMI2 is a maximum of EUR 9 000 000.
The indicative duration of the action is 60 months.
7. IMI2-2017-12-07: European Screening Centre: unique library for attractive biology (ESCulab)
The indicative in-kind contribution is EUR 18 250 000.
This contribution comprises an indicative EFPIA in-kind contribution of
EUR 17 500 000 and an indicative IMI2 Associated Partners in-kind
contribution of EUR 750 000.
The financial contribution from IMI2 JU is a maximum of EUR 18 250 000.
The indicative duration of the action is 60 months.
Deadline for proposals’ submission
The deadline of this call is 24 October 2017, 17:00 (Brussels local time) for the first stage, and 16 May 2018, 17:00 (Brussels local time) for the second stage.
Applicants must submit their proposal electronically, following the link on the submission service.
Further information
Please find attached the call documents.
More information: http://ec.europa.eu/research/participants/data/ref/h2020/other/call_fiches/jtis/h2020-call-fiche17-12-imi2-ju_en.pdf
Kind regards,
Flora Stavropoulou
Intern
European Office of Cyprus
Rue du Luxembourg 3, 2nd floor
B-1000, Brussels
Tel/Fax: +32 (0) 2 280 22 85
E-mail: eoc.brussels2@ucy.ac.cy
PLEASE NOTE THAT THE GREEK TRANSLATION IS PROVIDED AT REQUEST OF ANY INTERESTED MEMBER (based on the decision of 22.12.2016 of the EOC Administrative Council).
